Express Pharma

Albert David to tap new markets


In the last fiscal (2013-14), the company, touched a turnover of Rs 292 crores and is expecting to touch Rs 330 crores by March 2015

Kamal Prasad Mundhra

Kolkata-based pharmaceutical company Albert David, a unit of the Kothari group, has recently undertaken a range of initiatives for the development of new products for increasing its market share in formulation segment to achieve sustained growth in the current fiscal year.

“In the current fiscal, we have introduced new products and would be soon adding more brands to expand our product basket,” said Kamal Prasad Mundhra, Executive Director, Albert David.

Albert David, which makes pharma formulations, bulk drugs and injections, has three manufacturing plants — in Kolkata (for tablets and powder, small volume parenterals, oral liquids, bulk drugs), Ghaziabad (for IV fluids in glass and polythene containers using the latest Form-Fill-Seal (FFS) technology and small volume parenterals) and Mandideep (disposable syringes and needles).

In the last fiscal (2013-14), the company, touched a turnover of Rs 292 crores and is expecting to touch Rs 330 crores by March 2015.

The company has successfully launched Rabeprazole and its combination (Anti-peptic ulcerant range) and Montelukast and its combination (anti-asthmatic range).

New formulations have been launched in the therapeutic segments like anti-asthmatics (for the treatment of seasonal allergic rhinitis), anti-ulcerants another proton pump inhibitor and nutritional supplements in the treatment of patients with malnutrition, stress and convalescence, debility, etc.

During the current financial year, the company plans to further strengthen Alamin range of products by launching alamin liquid, alamin drops and other variants of L Arginine sachets.

He said, “We also have plans to venture into pre-probiotic, infertility and nutraceuticals market.”

Mundhra said, “The company has given much thrust on its research and development initiatives. The company has made significant investments in fully renovating and expanding its R&D facility at Kolkata. The facility had been further equipped with more analytical and functional instruments as well as manpower to enhance its R&D capability to deliver more advanced and efficacious dosage forms in oral solids, oral liquid and some APIs. A number of R&D projects in product and process development have been taken up, which is at different stages of development.”

To expand the geographical reach of the company’s products in export market, a number of dossiers have been submitted in different countries. Approval of some dossiers has been received during this financial year.

Commenting on the Indian pharma industry, he said it is an extremely fragmented market with severe price competition and government price control.

But inspite of these, Albert David will continue to grow with the current strategies in place and is equipped to meet any future challenges, he added.

EP New BureauKolkata

- Advertisement -

Comments are closed.